FIRST QUARTER IN BRIEF
- Preparations ongoing for start of the clinical proof of concept studies with tasquinimod in myelofibrosis
- The expansion cohort of the study in multiple myeloma is ongoing according to plan
EVENTS AFTER THE END OF THE PERIOD
- Start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (
April 3 )
FINANCIAL SUMMARY
SEK M | Jan-Mar | Full year | |
2024 | 2023 | 2023 | |
Net sales | - | - | - |
Operating profit/loss | -10.7 | -11.8 | -46.5 |
Profit/loss after tax | -10.5 | -11.5 | -45.8 |
Earnings per share (SEK) | -0.03 | -0.04 | -0.17 |
Cash and cash equivalents (at close of period) | 25.4 | 30.2 | 36.2 |
The report is also available at www.activebiotech.com.
This information was provided to the media, through the agency of the contact persons set out below, for publication on
© Modular Finance, source